Clinical Trial Update: Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 safety study of daily combination therapy with XL647 and XL147 in adults with solid tumors; the study has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• XL147 (SAR245408)
• XL647

Snippet

Sponsor: Exelixis | Conditions: Cancer, Non-small-cell Lung Cancer | Phase 1 | Status: WITHDRAWN